

November 29, 2018



Todos Medical to Present Scientific Abstract at the Upcoming San Antonio Breast Cancer Symposium (SABCS)

REHOVOT, Israel, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer, announced today that it will be attending the 2018 San Antonio Breast Cancer Symposium (SABCS) being held December 4-8, 2018, in San Antonio, Texas. At the SABCS, Todos Medical will present its scientific abstract discussing the most recent clinical trial results of its TM-B1 cancer test which consisted of 190 patients.

The annual SABCS is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer to an international audience of academic and private physicians and researchers.

"Presenting our scientific abstract at one of the leading symposiums on breast cancer is another important milestone for Todos Medical," said Herman Weiss, MD, FACOG, MBA, CEO of Todos Medical. "Publication of our scientific abstract affords Todos Medical the opportunity to relate our progress in our recently completed clinical trial to the scientific community. We believe that the findings described in the scientific abstract will demonstrate the effectiveness of our revolutionary approach to early cancer detection through a novel blood-based technology platform utilizing spectroscopic analysis of mononuclear cells and plasma."

About Todos Medical

Todos Medical Ltd. (OTCQB: TOMDF), an Israeli company headquartered in Rehovot, Israel, is a cancer in-vitro-diagnostic ("IVD") company engaging in the development of a series of blood tests for the early detection of a variety of cancers. The company has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer's influence on the immune system which triggers biochemical changes in peripheral blood mononuclear cells ("PBMC") and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company's two cancer screening tests, TM-B1 and TM-B2 are CE marked in the EU.

For more information, the content of which is not part of this press release, please visit <http://www.Todosmedical.com>.

Forward-looking statements: Certain statements contained in this press release may constitute forward-looking statements. For example, we use forward-looking statements when discussing our expected clinical development programs and clinical trials. These

forward-looking statements are based only on the current expectations of the management of Todos Medical, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance of Todos Medical to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, reference is made to Todos Medical's reports filed from time to time with the U.S. Securities and Exchange Commission.

Media Contact:

Todos Medical Ltd.
Daniel Hirsch
Investor Relations
Dan.h@todosmedical.com
(347) 699-0029



Source: Todos Medical Ltd.